Recently, EOCs have been reclassified according to their molecular features into type I (low grade serous, low grade endometrioid, all mucinous and clear cell carcinomas) and type II (high grade serous and endometrioid carcinomas) with mutations mainly in KRAS and PTEN in type I and mutations in TP53 in type II [25], [26]. Here, KRAS is linked to endometrioid adenocarcinoma.